Keyword: U.S. Supreme Court
Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its case.
Allergan took its tribal licensing deal all the way to the Supreme Court, which declined to hear the case.
Can tribal immunity shield a drug—in this case, Restasis—from a patent challenge? Allergan and the Mohawk tribe want the Supreme Court to weigh in.
Amgen failed to keep Repatha rival Praluent off the market with a patent challenge, but it's hoping more price cuts will help it grab market share.
In oral arguments Monday, liberal Justice Breyer and several conservative Justices appeared to support Merck's defense.
Monday was a good-news-bad-news day for Gilead as the Supreme Court handed down two decisions about which appeals they'll consider.
The U.S. is supporting Merck in the Fosamax case, which addresses the question of whether FDA decisions shield pharma from state suits.
An appeals court rejected a motion by J&J to issue an injunction against Zytiga generics, potentially opening the market as a patent case plays out.
Merck lost out when a judge nixed $200 million in patent damages, citing misconduct and fabricated testimony. Now it wants the Supreme Court to intervene.
An AIDS group is asking the court to consider claims that Gilead manipulated the patent system at the expense of patient safety.